KYTX – kyverna therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Kyverna Therapeutics (NASDAQ:KYTX) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Kyverna Therapeutics (NASDAQ:KYTX) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Kyverna Therapeutics GAAP EPS of -$0.85 misses by $0.04 [Seeking Alpha]
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
Form SCHEDULE 13G Kyverna Therapeutics, Filed by: GordonMD Global Investments LP
Form 10-Q Kyverna Therapeutics, For: Sep 30
Form 8-K Kyverna Therapeutics, For: Nov 12
Form 8-K Kyverna Therapeutics, For: Nov 02
Form 8-K Kyverna Therapeutics, For: Oct 29
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.